|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
over 100 countries
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
1992
|
|
gptkbp:ATCCode
|
gptkb:J07BC02
|
|
gptkbp:boosterRecommended
|
no
|
|
gptkbp:broadcastOn
|
two doses
|
|
gptkbp:canBeGivenWith
|
typhoid vaccine
hepatitis B vaccine
|
|
gptkbp:contains
|
inactivated hepatitis A virus
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
allergy to vaccine component
|
|
gptkbp:developedBy
|
gptkb:Sanofi_Pasteur
gptkb:Merck_&_Co.
gptkb:Crucell
GlaxoSmithKline
|
|
gptkbp:duration
|
at least 20 years
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
hepatitis A vaccine
|
|
gptkbp:immunityOnset
|
2–4 weeks after first dose
|
|
gptkbp:includedIn
|
childhood immunization schedules in some countries
|
|
gptkbp:indication
|
gptkb:men_who_have_sex_with_men
adults
children
travelers to endemic areas
people with chronic liver disease
people who use illicit drugs
|
|
gptkbp:intervalBetweenDoses
|
6 to 12 months
|
|
gptkbp:marketedAs
|
gptkb:Vaqta
gptkb:Avaxim
gptkb:Epaxal
gptkb:Havrix
|
|
gptkbp:notLiveVaccine
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prevention
|
gptkb:hepatitis_A
|
|
gptkbp:protectionRate
|
over 95% after two doses
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fatigue
headache
loss of appetite
soreness at injection site
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:type
|
vaccine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:hepatitis_A
|
|
gptkbp:bfsLayer
|
6
|